|

AKR1C3-activated Prodrug AST-3424 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: AKR1C3-activated Prodrug OBI-3424, AKR1C3-activated Prodrug TH-3424, AST-3424, Aldo-keto Reductase 1c3-activated Prodrug OBI-3424, OBI 3424 +5 more

Pipeline

Phase 1/2: 1

Top Sponsors

  • SWOG Cancer Research Network1

Indications

  • Refractory T Lymphoblastic Lymphoma1
  • Refractory T Acute Lymphoblastic Leukemia1
  • Recurrent T Acute Lymphoblastic Leukemia1
  • T-lymphoblastic Lymphoma1
  • Cancer1

Birmingham, Alabama1 trial

Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)

University of Alabama at Birmingham Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.